Loading search results
EuroECMO-COVID
Sponsor study identifier
observational
150
19 countries
97
Study Start
April 10, 2020
Actual (reported)Primary Completion
April 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
April 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
In the last 10 years, severe acute respiratory infection (SARI) was responsible of multiple outbreaks putting a strain on the public health worldwide. Indeed, SARI had a relevant role in the development of pandemic and epidemic with terrible consequences such as the 2009 H1N1 pandemic which led to more than 200.000 respiratory deaths globally. In late December 2019, in Wuhan, Hubei, China, a new respiratory syndrome emerged with clinical signs of viral pneumonia and person-to-person transmission. Tests showed the appearance of a novel coronavirus, namely the 2019 novel coronavirus (COVID-19). Two other strains, the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused severe respiratory illnesses, sometimes fatal. In particular, the mortality rate associated with SARS-CoV and MERS-CoV, was of 10% and 37% respectively. Even though COVID-19 appeared from the first time in China, quickly it spread worldwide and cases have been described in other countries such as Thailand, Japan, South Korea, Germany, Italy, France, Iran, USA and many other countries. An early paper reported 41 patients with laboratory-confirmed COVID-19 infection in Wuhan. The median age of the patients was 49 years and mostly men (73%). Among those, 32% were admitted to the ICU because of the severe hypoxemia. The most associated comorbidities were diabetes (20%), hypertension (15%), and cardiovascular diseases (15%). On admission, 98% of the patients had bilateral multiple lobular and sub-segmental areas of consolidation. Importantly, acute respiratory distress syndrome (ARDS) developed in 29% of the patients, while acute cardiac injury in 12%, and secondary infection in 10%. Invasive mechanical ventilation was required in 10% of those patients, and two of these patients (5%) had refractory hypoxemia and received extracorporeal membrane oxygenation (ECMO). In a later retrospective report by Wang and collaborators, clinical characteristics of 138 patients with COVID-19 infection were described. ICU admission was required in 26.1% of the patients for acute respiratory distress syndrome (61.1%), arrhythmia (44.4%), and shock (30.6%). ECMO support was needed in 11% of the patients admitted to the ICU. During the period of follow-up, overall mortality was 4.3%. The use of ECMO in COVID-19 infection is increasing due to the high transmission rate of the infection and the respiratory-related mortality. Therefore, the investigators believe that ECMO in case of severe interstitial pneumonia caused by COVID could represent a valid solution in order to avoid lung injuries related to prolonged treatment with non-invasive and invasive mechanical ventilation. In addition, ECMO could have a role for the systemic complications such as septic and cardiogenic shock as well myocarditis scenarios. Potential clinical effects and outcomes of the ECMO support in the novel coronavirus pandemic will be recorded and analyzed in our project. The researchers hypothesize that a significant percentage of patients with COVID-19 infection will require the utilize of ECMO for refactory hypoxemia, cardiogenic shock or septic shock. This study seeks to prove this hypothesis by conducting an observational retrospective/prospective study of patients in the ICU who underwent ECMO support and describe clinical features, severity of pulmonary dysfunction and risk factors of COVID-patients who need ECMO support, the incidence of ECMO use, ECMO technical characteristics, duration of ECMO, complications and outcomes of COVID-patients requiring ECMO support.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 10, 2020
Actual (reported)April 17, 2020
Actual (reported)April 29, 2020
Actual (reported)April 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
April 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Age
age in years
at baseline
Gender
male/female
at baseline
Weight
in kilograms
at baseline
Height
in meters
at baseline
patients with confirmed COVID-19 infection who require ECMO support
Universitätskliniken Innsbruck
Innsbruck, Austria
Landesklinikum Sankt Polten
Sankt Pölten, Austria
Medical University of Vienna
Vienna, Austria
Bolotin S, Pebody R, White PJ, McMenamin J, Perera L, Nguyen-Van-Tam JS, Barlow T, Watson JM; UK Severe Influenza Surveillance System (USISS) Steering Group. A new sentinel surveillance system for severe influenza in England shows a shift in age distribution of hospitalised cases in the post-pandemic period. PLoS One. 2012;7(1):e30279. doi: 10.1371/journal.pone.0030279. Epub 2012 Jan 23.
Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz MA, Krishnan A, Lal R, Montgomery JM, Molbak K, Pebody R, Presanis AM, Razuri H, Steens A, Tinoco YO, Wallinga J, Yu H, Vong S, Bresee J, Widdowson MA. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012 Sep;12(9):687-95. doi: 10.1016/S1473-3099(12)70121-4. Epub 2012 Jun 26.
Lorusso, Prof. Dr.
Maastricht University Hospital
First Submitted
April 17, 2020
First Posted
April 29, 2020
Study Start
April 10, 2020
Actual (reported)Primary Completion
April 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
BMI
weight and height combined to calculate BMI in kg/m\^2
at baseline
Pre-existing pulmonary disease y/n
Asthma y/n, cystic fibrosis y/n, chronic obstructive pulmonary disease y/n, pulmonary hypertension y/n, pulmonary fibrosis y/n, chronic restrictive lung disease y/n
at baseline
Main co-morbidities y/n
diabetes mellitus y/n, chronic renal failure y/n, ischemic heart disease y/n, heart failure y/n, chronic liver failure y/n, neurological impairment y/n
at baseline
Date of signs of COVID-19 infection
in dd-mm-yyyy or mm-dd-yyyy
at baseline or date of occurence
Date of positive swab
in dd-mm-yyyy or mm-dd-yyyy
at baseline or date of occurence
Pre-ECMO length of hospital stay
in days
at or during ECMO-implant
Pre-ECMO length of ICU stay
in days
at or during ECMO-implant
Pre-ECMO length of mechanical ventilation days
in days
at or during ECMO-implant
Use of antibiotics
y/n, what kind
up to 6 months
Use of anti-viral treatment
y/n, what kind
up to 6 months
Use of second line treatment
y/n, what kind (eg prone-position, recruitment manoeuvers, neuromuscular blockade etc)
up to 6 months
Indications for ECMO-implant
respiratory or cardiac
at ECMO-implant
Type of ECMO-implant
veno-venous, veno-arterial or veno-venoarterial
at ECMO-implant
Type of access
peripheral or central
at ECMO-implant
Date of ECMO implant
in dd-mm-yyyy or mm-dd-yyyy
at ECMO-implant
ECMO blood flow rate
l/min
from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months
ECMO gas flow rate
l/min
from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months
ECMO configuration change
y/n
up to 6 months
Date of ECMO configuration change
in dd-mm-yyyy or mm-dd-yyyy
up to 6 months
New ECMO configuration
veno-venous, veno-arterial, veno-venoarterial, other
up to 6 months
Indications for ECMO configuration change
right ventricular failure, left ventricular failure, refractory hypoxemia
up to 6 months
Ventilator setting on ECMO
settings of ventilator
from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months
Anticoagulation during ECMO
heparin, bivalirudin, nothing
from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months
Frequency of ECMO circuit change
amount of ECMO circuit changes (1, 2, 3 etc.)
up to 6 months
ECMO complications
Hemorrhagic, infection, other complications
up to 6 months
ECMO Weaning
y/n
from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months
ICU discharge
y/n, date
from day of ICU-admission for every 24 hours until date of discharge or death, up to 6 months
Main cause of death
6 months
Type of discharge
Ward, another ICU, rehabilitation center, home
up to 6 months
Alive/deceased
6 months
Contact the study team to confirm eligibility.
Onze Lieve Vrouwziekenhuis Aalst
Aalst, Belgium
University Hospital, Antwerp
Antwerp, Belgium
Centre Hospitalier Universitaire Saint Pierre
Brussels, Belgium
Chirec
Brussels, Belgium
Erasme University Hospital
Brussels, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
Hôpital Civil Marie Curie de Charleroi
Charleroi, Belgium
University Hospital, Ghent
Ghent, Belgium
La Louvière Hopital
La Louvière, Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
CHU de Liege
Liège, Belgium
Charles University, Czech Republic
Prague, Czechia
General University Hospital, Prague
Prague, Czechia
Copenhagen University Hospital at Herlev
Copenhagen, Denmark
University Hospital, Bordeaux
Bourdeaux, France
Hospices Civils de Lyon
Lyon, France
University Hospital, Montpellier
Montpellier, France
Henri Mondor University Hospital
Paris, France
Paris South University Hospitals
Paris, France
Pitié-Salpêtrière Hospital
Paris, France
Rennes University Hospital
Rennes, France
University Hospital, Aachen
Aachen, Germany
German Heart Center
Berlin, Germany
Universitätsklinikum Köln
Cologne, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Children's Medical Hospital, University of Essen, Essen, Germany
Essen, Germany
University Hospital, Essen
Essen, Germany
University Heart Center Freiburg - Bad Krozingen
Freiburg im Breisgau, Germany
Hannover Medical School
Hanover, Germany
Klinikum Kassel
Kassel, Germany
Heart Center Leipzig - University Hospital
Leipzig, Germany
Klinikum Nürnberg
Nuremberg, Germany
University Hospital Regensburg
Regensburg, Germany
University Hospital Tuebingen
Tübingen, Germany
University Hospital, Alexandroupolis
Alexandroupoli, Greece
Heim Pal Children's Hospital
Budapest, Hungary
ECMO Centers Israel
Jerusalem, Israel
San Giorgio Clinic
Alessandria, Italy
Ospedali Riuniti Ancona
Ancona, Italy
Papa Giovanni XXIII Hospital
Bergamo, Italy
St. Orsola Hospital
Bologna, Italy
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, Italy
Ospedale Maurizio Bufalini
Cesena, Italy
Gaslini Children's Hospital
Genoa, Italy
G. Pasquinucci Heart Hospital, Massa
Massa, Italy
Niguarda Hospital
Milan, Italy
Ospedale San Donato
Milan, Italy
San Raffaele University Hospital, Italy
Milan, Italy
Policlinico Hospital Milan
Milan, Italy
San Gerardo Hospital
Monza, Italy
IRCCS Policlinico S. Matteo
Pavia, Italy
GVM Care & Research
Puglia, Italy
Bambino Gesù Hospital and Research Institute
Roma, Italy
San Camillo Hospital, Rome
Roma, Italy
A.O.U. Città della Salute e della Scienza - Molinette Hospital
Turin, Italy
Mauriziano Umberto I Hospital
Turin, Italy
Ospedale S. Giovanni Bosco
Turin, Italy
University Hospital, Udine, Italy
Udine, Italy
Ospedale dell'Angelo, Venezia-Mestre
Venice, Italy
Ospedale San Bortolo di Vicenza
Vicenza, Italy
Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania
University of Groningen
Groningen, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
UMC Utrecht
Utrecht, Netherlands
Medical University of Warsaw
Warsaw, Poland
Hospital Sao Joao
Porto, Portugal
Chelyabinsk Regional Clinical Hospital
Chelyabinsk, Russia
Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash
Kemerovo, Russia
Krasnodar Regional Hospital no 1
Krasnodar, Russia
City Clinical Hospital No. 67, Moscow, Russia
Moscow, Russia
Novosibirsk City Hospital #2
Novosibirsk, Russia
City Hospital No 40, Saint Petersburg, Russia
Saint Petersburg, Russia
City Hospital No 41, Ekaterinburg, Russia
Yekaterinburg, Russia
Hospital Sant Joan de Deu
Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Miguel Servet
Zaragoza, Spain
Lund University Hospital
Lund, Sweden
Karolinska University Hospital
Stockholm, Sweden
University Hospital, Basel, Switzerland
Basel, Switzerland
University of Bern
Bern, Switzerland
University Hospital, Geneva
Geneva, Switzerland
University of Lausanne Hospitals
Lausanne, Switzerland
Cardiocentro Ticino
Lugano, Switzerland
Klinik Hirslanden, Zurich
Zurich, Switzerland
University of Zurich
Zurich, Switzerland
Royal Brompton & Harefield NHS Foundation Trust
Brompton, United Kingdom
Paediatric Intensive Care Glasgow
Glasgow, United Kingdom
Leicester Children's Hospital
Leicester, United Kingdom
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle upon Tyne, United Kingdom
Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, Van Kerkhove MD, Mounts AW, Paget WJ; GLaMOR Collaborating Teams. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med. 2013 Nov;10(11):e1001558. doi: 10.1371/journal.pmed.1001558. Epub 2013 Nov 26.
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.
Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003 May 15;348(20):1967-76. doi: 10.1056/NEJMoa030747. Epub 2003 Apr 10.
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ; SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003 May 15;348(20):1953-66. doi: 10.1056/NEJMoa030781. Epub 2003 Apr 10.
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012 Nov 8;367(19):1814-20. doi: 10.1056/NEJMoa1211721. Epub 2012 Oct 17.
de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013 Jul;87(14):7790-2. doi: 10.1128/JVI.01244-13. Epub 2013 May 15. No abstract available.
Spina S, Marrazzo F, Migliari M, Stucchi R, Sforza A, Fumagalli R. The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy. Lancet. 2020 Mar 14;395(10227):e49-e50. doi: 10.1016/S0140-6736(20)30493-1. Epub 2020 Feb 28. No abstract available.
Ebrahim SH, Memish ZA. COVID-19: preparing for superspreader potential among Umrah pilgrims to Saudi Arabia. Lancet. 2020 Mar 14;395(10227):e48. doi: 10.1016/S0140-6736(20)30466-9. Epub 2020 Feb 27. No abstract available.
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
De Piero ME, Mariani S, van Bussel BCT, Jarczak D, Krenner N, de la Sota EP, Silva PE, Roemmer M, Kowalewski M, Carelli S, Broman LM, Vuylsteke A, Fortuna P, Alessandri F, Martucci G, Patel BV, Lotz G, Boeken U, Maier S, Filip B, Meyns B, Haenggi M, Puss S, Schellongowski P, Kirali K, Bolotin G, Barrett N, Riera J, Mueller T, Belohlavek J, Lorusso R; EuroECMO-COVID Study Group. In-hospital outcomes and 6-month follow-up results of patients supported with extracorporeal membrane oxygenation for COVID-19 from the second wave to the end of the pandemic (EuroECMO-COVID): a prospective, international, multicentre, observational study. Lancet Respir Med. 2025 Apr;13(4):307-317. doi: 10.1016/S2213-2600(24)00369-2. Epub 2025 Feb 23.
Lorusso R, De Piero ME, Mariani S, Di Mauro M, Folliguet T, Taccone FS, Camporota L, Swol J, Wiedemann D, Belliato M, Broman LM, Vuylsteke A, Kassif Y, Scandroglio AM, Fanelli V, Gaudard P, Ledot S, Barker J, Boeken U, Maier S, Kersten A, Meyns B, Pozzi M, Pedersen FM, Schellongowski P, Kirali K, Barrett N, Riera J, Mueller T, Belohlavek J; EuroECMO-COVID Study Group. In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study. Lancet Respir Med. 2023 Feb;11(2):151-162. doi: 10.1016/S2213-2600(22)00403-9. Epub 2022 Nov 16.
Study Completion
April 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
September 5, 2021
Record last verified: 2021-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: